Terminated PHASE1 INTERVENTIONAL 2-arm NCT01072591

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

A Phase I, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess Safety,Tolerability, Pharmacokinetics and Efficacy of MEDI-578, an Anti-NGF Monoclonal Antibody, After Single Ascending Doses in Male and Non-fertile Female Patients With Painful Osteoarthritis of the Knee

Sponsor: AstraZeneca

Conditions Osteoarthritis Pain

Interventions MEDI-578 Placebo for MEDI-578

Updated 5 times since 2017 Last updated: Jan 28, 2013 Started: Feb 28, 2010 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Amended clinical development plan.

Other terminated trials from AstraZeneca

See all terminations from AstraZeneca

Other Osteoarthritis trials with similar outcome

Browse all Osteoarthritis trials

A PHASE1 clinical study on Osteoarthritis and Pain, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 5 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Feb 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
MedImmune LLC

Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London Bridge, United Kingdom